Fanapt growth of 26% year-over-year was primarily driven by the 2024 bipolar I disorder label expansion, which management identifies as the key volume catalyst. The company launched Nirius via a pioneering direct-to-consumer (DTC) platform to bypass traditional pharmacy barriers and address a market of 70 million motion sickness sufferers. Management attributes the Q1 sequential revenue decline to industry-standard insurance plan disruptions and deductible resets rather than a shift in underlying dema ...